Archived article. This article was published by Synergus RWE on 18 May 2016 and is kept for reference. For current insights visit athagoras Medtech.
The changing landscape in Germany regarding HTA assessments
The changing landscape in Germany regarding HTA assessments
The German landscape for introduction of new technologies and drugs is changing dramatic. For drugs, the introduction of the Amnog process has been a drastic change. Now the medical devices are undergoing a similar drastic change, where new medical technologies coming to market through the innovation funding pathway have to go through a benefit assessment.
Below are statistics regarding the development of HTA activity in Germany. It does not only include HTAs, but also the important guidelines published from G-BA.
Learn more about our services here:
Related articles
- Introduction of benefit assessment requires complete rethink about how to handle nub-applications for new interventions30 May 2016
- Health technology assessments of in-vitro diagnostic tests 12 Apr 2016
- Integration of Treatment council to The Danish Healthcare Quality Institute (DHQI) - Impacting Medtech and Diagnostics23 May 2025